Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556033 | 1.00 | LMNA (0.35) | LMNATP53ALDH1A1TSHRHTR2A | |
| SCHEMBL21173640 | 0.87 | TP53 (0.42) | TP53ALDH1A1TSHRHTR2AHTR2C | |
| SCHEMBL27447426 | 0.85 | TP53 (0.40) | TP53ALDH1A1TSHRHTR2AHTR2C | |
| SCHEMBL28337793 | 0.85 | TP53 (0.40) | TP53ALDH1A1TSHRHTR2AHTR2C | |
| SCHEMBL609519 | 0.84 | TSHR (0.38) | LMNATP53ALDH1A1TSHR | |
| SCHEMBL22566347 | 0.77 | SMN1; SMN2 (0.37) | ALDH1A1 | |
| SCHEMBL28698290 | 0.77 | SMN1; SMN2 (0.37) | ALDH1A1 | |
| SCHEMBL10011553 | 0.77 | TP53 (0.38) | TP53ALDH1A1TSHRCYP1A2GAA | |
| SCHEMBL10011557 | 0.77 | TP53 (0.38) | TP53ALDH1A1TSHRCYP1A2GAA | |
| SCHEMBL1164602 | 0.77 | TSHR (0.46) | LMNAALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| EP-3955926-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107899-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2021-04-15 | — | — | US | disclosed |
| US-10875845-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2020-12-29 | — | — | US | disclosed |
| US-20200331896-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | US | disclosed |
| WO-2020212755-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107899-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | LMNA 1999/4885TP53 2979/4885ALDH1A1 489/4885 |
| US-20200331896-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | LMNA 1999/4885TP53 2979/4885ALDH1A1 489/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | LMNA 1999/4885TP53 2979/4885ALDH1A1 489/4885 |
| US-10875845-B2 | Compounds and methods for the treatment of ocular disorders | MUC1, MPO, SERPINB1 | LMNA 1999/4885TP53 2979/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.